Skip to main content

Advertisement

Table 2 Participant response to treatment over 28-day follow-up among participants in a therapeutic efficacy study in Machinga, Nkhotakota, and Karonga Districts in Malawi, 2014 (n = 452)

From: In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for uncomplicated Plasmodium falciparum malaria in Malawi, 2014

Estimate AL ASAQ
Total (n = 338) Site Total (n = 114)
Machinga (n = 112) Nkhotakota (n = 113) Karonga (n = 113)
Participants lost to follow-up, n (%) 35 (10.4) 14 (12.5) 15 (13.3) 6 (5.3) 16 (14)
Treatment failure, n (%)
 Early 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
 Late 72 (23.8) 22 (22.5) 31 (31.6) 19 (17.8) 3 (3.1)
  Day of failure, median (range) 21 (14, 28) 24.5 (14, 28) 21 (14, 28) 21 (14, 28) 14 (14, 21)
  Reinfection* 70 (23.1) 22 (22.5) 31 (31.6) 17 (15.9) 2 (2)
  Recrudescence 2 (0.66) 0 (0) 0 (0) 2 (1.9) 1 (1)
 Day 3 clearance,  % (95 % CI)a 99.7 (98.3–100) 99.1 (94.5–100) 100 (96.7–100) 100 (96.7–100) 100 (96.7–100)
ACPR,  % (95 % CI)b
  Uncorrected 76.2 (71–80.9) 77.6 (68–83.4) 68.4 (58.2–77.4) 82.2 (73.7–89) 96.9 (91.3–99.4)
  PCR-corrected 99.3 (97.6–99.9) 100 (96.3–100) 100 (96.3–100) 98.1 (93.4–100) 99 (94.5–100)
Kaplan–Meier survival rate on day 28, % (95 % CI)c
 Uncorrected 76.8 (72.1–81.5) 78.2 (70.2–86.3) 69 (59.9–78.1) 82.5 (75.4–89.7) 97.1 (93.9–100)
 PCR-corrected 99.3 (98.3–100) 100d 100d 98.0 (95.3–100) 99.0 (97.2–100)
  1. * Significant difference between study sites (p < 0.05)
  2. aPercent day 3 clearance was estimated only among participants still enrolled in the study on day 3
  3. bAdequate clinical and parasitologic response (ACPR) was estimated only among participants who reached a valid study endpoint
  4. cThe Kaplan–Meier cumulative survival rate estimate included all study participants who contributed person-days during the 28-day follow-up
  5. dFor Kaplan–Meier cumulative survival rates of 100 %, confidence intervals were not estimated